Challenges in treating Pompe disease: an industry perspective.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Pompe disease is a rare inherited metabolic disorder caused by deficient acid alpha-glucosidase (GAA).
• Alglucosidase alfa (rhGAA ERT) is the sole approved treatment, offering clinical benefits but facing limitations.

Purpose of the Study:

• To review the challenges hindering optimal drug targeting and clinical efficacy of alglucosidase alfa ERT.
• To discuss implications for next-generation Pompe disease therapies, including gene therapies.

Main Methods:

• Literature review of alglucosidase alfa enzyme replacement therapy (ERT) over the past two decades.
• Analysis of factors affecting ERT effectiveness, including drug design and anatomical limitations.

Main Results:

• Alglucosidase alfa ERT demonstrates clinical benefits but suffers from poor drug targeting to skeletal muscles.
• Inefficiency is attributed to inherent anatomical factors and areas for improvement in drug design.

Conclusions:

• Overcoming current ERT limitations requires addressing drug targeting and delivery inefficiencies.
• These insights are crucial for developing improved enzyme and gene therapies for Pompe disease.